Current status of therapy for breast cancer worldwide and in Japan

por Park, Youngjin, Kitahara, Tomoaki, Takagi, Ryuichi, Kato, Ryoji
Publicado em 2011

Expected clinical applications of circulating tumor cells in breast cancer

por Park, Youngjin, Kitahara, Tomoaki, Urita, Tasuku, Yoshida, Yutaka, Kato, Ryoji
Publicado em 2011

Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab

por Kato, Ryoji, Hayashi, Hidetoshi, Tanizaki, Junko, Tanaka, Kaoru, Takeda, Masayuki, Nakagawa, Kazuhiko
Publicado no ESMO Open (2017)

Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb‐202 in gastric cancer

por Sakai, Hitomi, Kawakami, Hisato, Teramura, Takeshi, Onodera, Yuta, Somers, Elizabeth, Furuuchi, Keiji, Uenaka, Toshimitsu, Kato, Ryoji, Nakagawa, Kazuhiko
Publicado no Clin Transl Med (2021)

Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations

por Masago, Katsuhiro, Fujita, Shiro, Muraki, Miho, Hata, Akito, Okuda, Chiyuki, Otsuka, Kyoko, Kaji, Reiko, Takeshita, Jumpei, Kato, Ryoji, Katakami, Nobuyuki, Hirata, Yukio
Publicado no BMC Cancer (2015)

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

por Haratani, Koji, Hayashi, Hidetoshi, Chiba, Yasutaka, Kudo, Keita, Yonesaka, Kimio, Kato, Ryoji, Kaneda, Hiroyasu, Hasegawa, Yoshikazu, Tanaka, Kaoru, Takeda, Masayuki, Nakagawa, Kazuhiko
Publicado no JAMA Oncol (2017)

Gamma‐aminobutyric acid transaminase genetic polymorphism is a candidate locus for responsiveness to opioid analgesics in patients with cancer pain: An exploratory study

por Yokoshima, Yaeko, Sumitani, Masahiko, Nishizawa, Daisuke, Nagashima, Makoto, Ikeda, Kazutaka, Kato, Ryoji, Hozumi, Jun, Abe, Hiroaki, Azuma, Kenji, Tsuchida, Rikuhei, Yamada, Yoshitsugu
Publicado no Neuropsychopharmacol Rep (2018)

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts

por Kato, Ryoji, Haratani, Koji, Hayashi, Hidetoshi, Sakai, Kazuko, Sakai, Hitomi, Kawakami, Hisato, Tanaka, Kaoru, Takeda, Masayuki, Yonesaka, Kimio, Nishio, Kazuto, Nakagawa, Kazuhiko
Publicado no Br J Cancer (2020)

Evaluation of discomfort and tolerability to bronchoscopy according to different sedation procedures with midazolam

por MATSUMOTO, TAKESHI, OTSUKA, KOJIRO, KATO, RYOJI, SHIMIZU, RYOKO, OTOSHI, TAKEHIRO, FUJIMOTO, DAICHI, KAWAMURA, TAKAHISA, TAMAI, KOJI, NAGATA, KAZUMA, OTSUKA, KYOKO, NAKAGAWA, ATSUSHI, TOMII, KEISUKE
Publicado no Exp Ther Med (2015)

Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer

por Fujimoto, Daichi, Kato, Ryoji, Morimoto, Takeshi, Shimizu, Ryoko, Sato, Yuki, Kogo, Mariko, Ito, Jiro, Teraoka, Shunsuke, Nagata, Kazuma, Nakagawa, Atsushi, Otsuka, Kojiro, Tomii, Keisuke
Publicado no PLoS One (2016)

The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma

por Sato, Yuki, Fujimoto, Daichi, Uehara, Keiichiro, Shimizu, Ryoko, Ito, Jiro, Kogo, Mariko, Teraoka, Shunsuke, Kato, Ryoji, Nagata, Kazuma, Nakagawa, Atsushi, Otsuka, Kojiro, Hamakawa, Hiroshi, Takahashi, Yutaka, Imai, Yukihiro, Tomii, Keisuke
Publicado no BMC Cancer (2016)

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer

por Iwasa, Tsutomu, Tsurutani, Junji, Watanabe, Satomi, Kato, Ryoji, Mizuno, Yutaka, Kojima, Yasuyuki, Takashima, Tsutomu, Matsunami, Nobuki, Morimoto, Takashi, Yamamura, Jun, Ohtani, Shoichiro, Tanabe, Yuko, Yoshinami, Tetsuhiro, Takano, Toshimi, Komoike, Yoshifumi, Nakagawa, Kazuhiko
Publicado no BMC Cancer (2019)

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

por Yonesaka, Kimio, Iwama, Eiji, Hayashi, Hidetoshi, Suzuki, Shinichiro, Kato, Ryoji, Watanabe, Satomi, Takahama, Takayuki, Tanizaki, Junko, Tanaka, Kaoru, Takeda, Masayuki, Sakai, Kazuko, Azuma, Koichi, Chiba, Yasutaka, Atagi, Shinji, Nishio, Kazuto, Okamoto, Isamu, Nakagawa, Kazuhiko
Publicado no Sci Rep (2019)

U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation

por Haratani, Koji, Yonesaka, Kimio, Takamura, Shiki, Maenishi, Osamu, Kato, Ryoji, Takegawa, Naoki, Kawakami, Hisato, Tanaka, Kaoru, Hayashi, Hidetoshi, Takeda, Masayuki, Maeda, Naoyuki, Kagari, Takashi, Hirotani, Kenji, Tsurutani, Junji, Nishio, Kazuto, Doi, Katsumi, Miyazawa, Masaaki, Nakagawa, Kazuhiko
Publicado no J Clin Invest (2019)

Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L)

por Kato, Ryoji, Hayashi, Hidetoshi, Chiba, Yasutaka, Miyawaki, Eriko, Shimizu, Junichi, Ozaki, Tomohiro, Fujimoto, Daichi, Toyozawa, Ryo, Nakamura, Atsushi, Kozuki, Toshiyuki, Tanaka, Kentaro, Teraoka, Shunsuke, Usui, Kazuhiro, Nishino, Kazumi, Hataji, Osamu, Ota, Keiichi, Ebi, Noriyuki, Saeki, Sho, Akazawa, Yuki, Okuno, Motoyasu, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko
Publicado no J Immunother Cancer (2020)